Jeanne Anderson
Anchorage, AKNPI 1851334346
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by Johnson & Johnson at 48.8% of the total. Reporting peaked in 2023 at $75 and has fallen 55.3% since, to $34 in 2025.
Across 8 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$75
- AbbVie$34
- Pfizer$19
- Astellas Pharma US Inc$14
- Gilead$12
Across 60 payments — averaging $16,610 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$926K
- Pfizer$37K
- Astrazeneca UK Limited$17K
- Eli Lilly$17K
What the payments were for
- Food & beverage$6743%
- Education$8757%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $75 |
| AbbVie | 1 | $34 |
| Pfizer | 4 | $19 |
| Astellas Pharma US Inc | 1 | $14 |
| Gilead | 1 | $12 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.